Gilead Sciences, Inc. GILD announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1. PURPOSE 1 is a phase III, double-blind, randomized study evaluating the safety ...
Source LinkGilead Sciences, Inc. GILD announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1. PURPOSE 1 is a phase III, double-blind, randomized study evaluating the safety ...
Source Link
Comments